- Home
- AMIX vs ONVO Comparison
AMIX vs ONVO Comparison
Compare AMIX & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- ONVO
- Stock Information
- Founded
- AMIX 2014
- ONVO 2007
- Country
- AMIX United States
- ONVO United States
- Employees
- AMIX N/A
- ONVO N/A
- Industry
- AMIX
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMIX
- ONVO Health Care
- Exchange
- AMIX NYSE
- ONVO Nasdaq
- Market Cap
- AMIX 5.5M
- ONVO 5.3M
- IPO Year
- AMIX N/A
- ONVO N/A
- Fundamental
- Price
- AMIX $2.97
- ONVO $0.37
- Analyst Decision
- AMIX
- ONVO
- Analyst Count
- AMIX 0
- ONVO 0
- Target Price
- AMIX N/A
- ONVO N/A
- AVG Volume (30 Days)
- AMIX 58.5K
- ONVO 103.2K
- Earning Date
- AMIX 02-13-2025
- ONVO 02-19-2025
- Dividend Yield
- AMIX N/A
- ONVO N/A
- EPS Growth
- AMIX N/A
- ONVO N/A
- EPS
- AMIX N/A
- ONVO N/A
- Revenue
- AMIX N/A
- ONVO $122,000.00
- Revenue This Year
- AMIX N/A
- ONVO $59.08
- Revenue Next Year
- AMIX N/A
- ONVO $18.24
- P/E Ratio
- AMIX N/A
- ONVO N/A
- Revenue Growth
- AMIX N/A
- ONVO N/A
- 52 Week Low
- AMIX $2.55
- ONVO $0.32
- 52 Week High
- AMIX $93.80
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- AMIX 47.86
- ONVO 49.60
- Support Level
- AMIX $2.76
- ONVO $0.33
- Resistance Level
- AMIX $2.95
- ONVO $0.40
- Average True Range (ATR)
- AMIX 0.16
- ONVO 0.03
- MACD
- AMIX 0.08
- ONVO 0.00
- Stochastic Oscillator
- AMIX 72.83
- ONVO 61.25
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.